Head-To-Head Lung Data Support Boehringer’s Gilotrif Over Iressa
Final results from the LUX-Lung 7 trial suggest superior efficacy for Boehringer’s EGFR inhibitor Gilotrif vs. AstraZeneca’s Iressa, albeit with a small absolute improvement in progression-free survival and a higher rate of severe diarrhea.
You may also be interested in...
With Gilotrif sales building over time, private Boehringer Ingelheim turns its focus to broad development program for its third-generation EGFR inhibitor olmutinib, with ambition to become a leader in lung cancer.
ESMO In Brief: PD-1 Updates, Perjeta’s Striking Survival, Boehringer’s Gilotrif Head-to-Head EGFR Data & More
Data for Merck’s Keytruda in bladder cancer and AstraZeneca’s CTLA-4/PD-L1 combo were among the immunotherapy updates at the 2014 ESMO meeting. Other notable releases include Perjeta’s striking survival data, a possible reprieve in lung for Endocyte’s vintafolide and head-to-head lung cancer data for Boehringer’s afatinib.
It’s become commonplace to see monthly pricing of $10,000 for new cancer drugs, but with competition in mind Boehringer takes a conservative approach with its non-small-cell lung cancer drug Gilotrif (afatinib).